<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087008</url>
  </required_header>
  <id_info>
    <org_study_id>AZABACHE: 2009-017440-13</org_study_id>
    <nct_id>NCT01087008</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse</brief_title>
  <acronym>AZABACHE</acronym>
  <official_title>Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynamic Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and
      asymptomatic biochemical relapse

      It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with
      Multiple Myeloma in biochemical relapse. The following must be noted:

        -  Patients with no formal indication for chemotherapy treatment will be included, as
           patients with symptomatic myeloma who after responding show biochemical relapse are
           generally not treated. This allows for generating both a group of patients untreated, on
           no additional treatment and a treatment group on zoledronic acid.

        -  As these are relapsing symptomatic patients, their number is far higher than patients
           with quiescent Multiple Myeloma. This allows for expecting a good enrolment.

        -  There are few reliable data on symptom progression after biochemical relapse, though it
           is one of the new objectives occurring in almost all clinical trials on myeloma. In the
           VISTA study, it has been estimated that the median time to the new treatment is 5 months
           (combining progression-free time and time to the next treatment). This time is much
           shorter than the median quiescent myeloma progression-free survival, so a very long
           follow-up time will not be necessary in this patient group.

        -  The administration of this drug to these patients can help prevent skeleton-related
           complications in the future, the study of which will be a secondary objective of this
           study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zometa is administrated every 4 weeks at dose of 4 mg. The limit of administrations is 12.
      The first infusion is in the visit 2 and the last is in visit 13
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next need treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Time to the next treatment, considered as the time from the randomization date to the start of the next chemotherapy treatment for Multiple Mieloma or death for any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to symptom relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Time to symptom relapse, considered as the time from randomization to symptom relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease progression</measure>
    <time_frame>2 years</time_frame>
    <description>To describe the differences between patients treated with ZOL or not in terms of type of disease progression (bone and extra-bone).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic factors</measure>
    <time_frame>2 years</time_frame>
    <description>To describe the prognostic factors in patients with MM and asymptomatic biochemical relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antitumour effect of ZOL</measure>
    <time_frame>1 year</time_frame>
    <description>To assess the antitumour effect of ZOL on other clinically significant parameters in MM, including tumour response to ZOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">103</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Zoledronate acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments</description>
    <arm_group_label>Zoledronate acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment control</intervention_name>
    <description>Patients doesn't receive treatment</description>
    <arm_group_label>No treatment control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥18 years.

          -  Signed informed consent before performing any study procedure that is not the part of
             the regular medical care of the patients.

          -  Diagnosis of MM, with biochemical relapse after initial response with no symptoms
             resulting from the disease (CRAB), defined as a re-positivation of a previous
             immunofixation (two samples) or increase above 25% of serum or urine protein M.

          -  In the investigator's opinion, ability to meet all clinical trial requirements

        Exclusion Criteria:

          -  Treatment with bisphosphonates (oral route and/or endovenous route) within 3 months
             prior to inclusion.

          -  Treatment with denosumab within three months prior to inclusion.

          -  Criteria of symptomatic disease or organic damage related to disease, defined as:

               -  Impaired renal function: serum creatinine &gt;2 mg/dl or 173 mmol/l. Calcium
                  increase: serum calcium ≥12 mg/dl within 28 days prior to inclusion.

          -  Anaemia: haemoglobin &lt; 10 g/dl or 2 g/dl below normal ranges.

          -  Bone injury: new osteolytic lesions (from diagnosis) seen within 3 months prior to
             inclusion, current pathological fractures or increase of osteopenia (from diagnosis)
             in bone radiology series.

          -  Others: amyloidosis with current organic damage, recurrent bacterial infections (more
             than 2 events in 12 months), symptomatic hyperviscosity, presence of plasmacytomas.

          -  Patients with current and active dental disorders (dental, jaw infection, bone exposed
             in the mouth, jaw osteonecrosis).

          -  Patients developing jaw osteonecrosis or other serious adverse events due to treatment
             with any bisphosphonate .

          -  Significant liver disease:

          -  Bilirubin &gt; 3 g/dl.

          -  ALT &gt; 2.5 x the upper limit of normal

          -  AST &gt; 2.5 x the upper limit of normal

          -  Patients who are currently in another clinical trial or receiving any investigational
             agent.

          -  Pregnancy or nursing.

          -  Parathyroid gland diseases.

          -  Previous malignancy with a high risk of death or bone disease: breast cancer, prostate
             cancer or lung cancer, even if on complete response.

          -  Active presence of neoplasms other than Multiple Myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>García Sanz Ramon, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>PETHEMA Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jose María Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset.</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.novartis.es</url>
    <description>Novartis web page</description>
  </link>
  <link>
    <url>http://aehh.org</url>
    <description>Spnish Association of Haematology</description>
  </link>
  <results_reference>
    <citation>R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL ANTIMYELOMA EFFECT OF ZOLEDRONIC ACID IN PATIENTS WITH ASYMPTOMATIC BIOCHEMICAL RELAPSES. Abstract for ASH 2012</citation>
  </results_reference>
  <results_reference>
    <citation>R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL ANTIMYELOMA EFFECT OF ZOLEDRONIC ACID IN PATIENTS WITH ASYMPTOMATIC BIOCHEMICAL RELAPSES. Abstract for EHA 2012</citation>
  </results_reference>
  <results_reference>
    <citation>R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL ANTIMYELOMA EFFECT OF ZOLEDRONIC ACID IN PATIENTS WITH ASYMPTOMATIC BIOCHEMICAL RELAPSES. Poster for EHA 2012</citation>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

